300147 *ST香雪制药
2026/09 - 九个月
人民幣(K¥)
与去年同期
比较
2025/12
人民幣(K¥)
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
营业总收入1,064,124-7.14%1,595,4071,858,6622,299,2882,187,070
减:营业总成本1,227,079-13.19%1,970,9412,266,7422,452,4742,575,669
    其中:营业成本726,028-7.40%1,159,4681,405,8071,509,5211,643,173
               财务费用178,382-12.35%276,612231,011241,471212,510
               资产减值损失(13,687)-46.73%(544,408)(380,109)(163,342)(138,578)
公允价值变动收益(886)-240.75%(780)6362,728(12)
投资收益(1,210)-367.76%(835)(6,000)(50,640)47,329
    其中:对联营企业和合营企业的投资收益(1,240)142.65%(984)(1,343)(52,159)903
营业利润(160,854)-41.97%(922,598)(784,525)(332,716)(464,142)
利润总额(366,053)9.20%(1,336,835)(842,071)(388,951)(511,864)
减:所得税费用19,112394.33%33,94919,15412,795(7,215)
净利润(385,166)13.59%(1,370,785)(861,224)(401,746)(504,648)
减:非控股权益32,63043.02%21,386(2,664)(12,782)25,410
股东净利润(417,795)15.44%(1,392,171)(858,560)(388,964)(530,058)

市场价值指针
每股收益 (元) *-0.63014.55%-2.110-1.300-0.590-0.800
每股派息 (元) *------------
每股净资产 (元) *-1.169-211.59%-0.5451.5952.9113.637
审计意见 #--带持续经营重大不确定性段落的无保留意见标准的无保留意见保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容